Happy New Year: Here Are 2 Stocks to Watch Going Into 2026

Tesla intends to begin mass production of its dedicated Cybercab in April with the single biggest production expansion slated for Q2 2026, but the commercial thesis hinges on obtaining regulatory approvals for unsupervised robotaxis and achieving aggressive unit economics (target cited: $0.20 per mile). Boeing, under CEO Kelly Ortberg, is prioritizing debt reduction and a 737 MAX production ramp—management plans to raise output by five aircraft per month in six-month increments targeting 42/month by end-2025, 47/month mid-2026 and 52/month by year-end—while improving margins in defense/space by avoiding costly program charges to convert 2024–25 outflows into free cash flow in 2026 and beyond.

Analysis

Market structure: Tesla's Cybercab rollout (mass production slated April 2026) creates winners (Tesla, ride‑hailing economics, data/AI suppliers) and losers (used‑car values, traditional OEMs making high‑feature consumer cars). Boeing's planned MAX ramp (42→47→52/mo through 2026) benefits airframe suppliers and airlines with delivery schedules, while pressuring cash needs for less diversified aerospace peers. Cross‑asset: successful Boeing ramp should ease credit spreads on BA debt and support industrial commodity demand (aluminum, titanium); a Tesla regulatory setback would spike TSLA implied vol >50% and could depress USD cyclical flows into autos/tech.

Risk assessment: Tail risks include a robotaxi fatality or regulatory ban (low probability, >30% immediate equity drawdown for TSLA) and Boeing experiencing further manufacturing defects or a credit downgrade (could force equity dilution). Time horizons: immediate (days) volatility around regulatory/production announcements, short‑term (3–9 months) revenue/margin impacts from U.S. EV tax credit expiry (end‑Sept 2026) and Boeing delivery cadence, long‑term (2–5 years) potential secular shifts in mobility and narrow‑body program funding. Hidden dependencies: TSLA economics hinge on <$0.20/mile unit costs and regulatory approvals that are jurisdictional; BA cash flow recovery depends on supplier stability and avoiding fixed‑price program overruns.

Trade implications: Favor asymmetric, catalyst‑linked positions. For BA, a 1–3% long equity + 9–12 month bull‑call spread (strike window anchored to 20–30% upside) sized to risk budget targets exposure to the delivery ramp while capping downside; cut if monthly build rate misses the 47/mo target by >10% for two consecutive months. For TSLA, prefer time‑staggered option exposure: small (0.5–1% risk) Jan 2028 LEAP 15–25% OTM call spread to capture robotaxi upside, and sell short‑dated (30–90 day) premium ahead of known regulatory milestones to finance it. Rotate 2–4% from legacy auto/ICE‑exposed names into aerospace suppliers and select semicap names (NVDA beneficiary of AV compute demand) over 6–12 months.

Contrarian angles: Consensus underprices regulatory friction — approvals will likely be stepwise and jurisdictional, not binary, so TSLA is underinsured for downside and overvalued for immediate monetization claims. Conversely, markets may be underestimating Boeing’s ability to convert backlog into free cash flow; if BA hits 47/mo by mid‑2026 and avoids D&SS charges, 12–18 month upside could be 30–50%. Historical parallels: aircraft production rebounds (post‑737 MAX) and tech platform rollouts (smartphone era) show multi‑year payoffs but punctuated by 30–50% interim drawdowns; position sizing and explicit stop/triggers are therefore critical.

Key Decisions for Investors

• Establish a 1–3% long position in Boeing (BA) common stock and hedge cost with a 9–12 month bull‑call spread sized to total risk = 1.5% of portfolio; divest if BA misses the 47/month production target by >10% for two consecutive months or if D&S margins remain <5% in sequential quarters through Q3 2026.
• Allocate 0.5–1% risk to a Tesla (TSLA) Jan 2028 15–25% OTM call spread (buy LEAP calls, sell higher strike) to capture robotaxi upside while limiting premium outlay; increase to 2% only after a verifiable unsupervised robotaxi approval in a major U.S. jurisdiction (CA, NV, or TX) within 60–90 days of April 2026 production start.
• Sell short‑dated (30–90 day) TSLA call or put premium around known regulatory/corporate milestones to finance longer‑dated LEAP exposure; target collecting premium to reduce net LEAP cost by ≥30% while keeping gross directional exposure capped at 1% risk.
• Reallocate 2–4% from legacy ICE‑centric auto exposure into aerospace suppliers and select AI/compute beneficiaries (e.g., NVDA) over 6–12 months; specifically, increase NVDA exposure by 0.5–1% to capture compute demand from AV stacks, and reduce ICE/labor‑intensive OEM exposure by 2% due to long odds of rapid product‑mix shift.
• Monitor and act on these catalysts within 30–90 day windows: (1) regulatory approvals for unsupervised robotaxis (state filings/permits in CA/NV/TX), and (2) BA monthly delivery reports hitting 47/mo by June 2026; use these binary events to scale positions up or down and set hard stop losses of 20–30% on option positions and 15% on equity exposures.